Soleno Therapeutics Appoints New CMO and CSO, CMO Departs
Ticker: SLNO · Form: 8-K · Filed: 2024-04-22T00:00:00.000Z
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Soleno Therapeutics shakes up leadership: Geller is new CMO, D. Smith is new CSO, R. Smith is out as CMO.
AI Summary
On April 17, 2024, Soleno Therapeutics, Inc. announced the appointment of Dr. Jonathan M. Geller as Chief Medical Officer and Dr. David M. D. Smith as Chief Scientific Officer. The company also reported the departure of Dr. Robert L. Smith as Chief Medical Officer. These changes are effective immediately.
Why It Matters
Key leadership changes in medical and scientific roles can signal shifts in the company's strategic direction and research priorities.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in medical and scientific roles, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Soleno Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Geller (person) — Appointed Chief Medical Officer
- Dr. David M. D. Smith (person) — Appointed Chief Scientific Officer
- Dr. Robert L. Smith (person) — Departed Chief Medical Officer
- April 17, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer at Soleno Therapeutics?
Dr. Jonathan M. Geller has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Scientific Officer?
Dr. David M. D. Smith has been appointed as the new Chief Scientific Officer.
Who has departed from their role as Chief Medical Officer?
Dr. Robert L. Smith has departed from his role as Chief Medical Officer.
What is the effective date of these leadership changes?
The changes are effective as of April 17, 2024.
What is the principal executive office address for Soleno Therapeutics?
The principal executive offices are located at 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 13 · Accepted 2024-04-22 16:15:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d818557d8k.htm (8-K) — 22KB
- 0001193125-24-104871.txt ( ) — 141KB
- slno-20240417.xsd (EX-101.SCH) — 3KB
- slno-20240417_lab.xml (EX-101.LAB) — 18KB
- slno-20240417_pre.xml (EX-101.PRE) — 11KB
- d818557d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: April 22, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer